Central sensitization in adolescents with hypermobility spectrum disorder or hypermobile Ehlers-Danlos syndrome-a feasibility study.
Central sensitization
Ehlers-Danlos syndrome
Feasibility study
Hypermobility
Pain
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
14 Jun 2023
14 Jun 2023
Historique:
received:
05
05
2022
accepted:
16
05
2023
medline:
15
6
2023
pubmed:
15
6
2023
entrez:
14
6
2023
Statut:
epublish
Résumé
Pain is a major symptom in adolescents with hypermobility spectrum disorder or hypermobile Ehlers-Danlos syndrome. Although the underlying mechanism causing generalized pain in children with hypermobility spectrum disorder or hypermobile Ehlers-Danlos syndrome is unclear, central sensitization has been suggested as a possible explanation. The aim of this study was to explore the feasibility of a study protocol for a future case-control study, investigating features of central sensitization in adolescents with hypermobility spectrum disorder or hypermobile Ehlers-Danlos syndrome. Central sensitization features were measured in ten patients and nine healthy controls aged 13-17 years via experimental pain measurement quantifying primary and secondary hyperalgesia, endogenous pain modulation, and exercise-induced hyperalgesia. Descriptive statistics were used. Frequency, median, and range values were calculated. Eleven out of 57 patients chose to participate. No control could be recruited through public schools. Therefore, a convenience sampling strategy was used for the recruitment of the control group. The process of assessing primary and secondary hyperalgesia, endogenous pain modulation, and exercise-induced hyperalgesia was well tolerated by all participants (patients and controls). When assessing endogenous pain modulation via conditioned pain modulation, two participants in the patient group and three in the control group did not achieve a pain experience ≥ 3 on the numerical rating scale when immersing their hands in cold water. This study investigated the feasibility, safety, and toleration of experimental pain measurements in adolescents with hypermobility spectrum disorder or hypermobile Ehlers-Danlos syndrome. Although the test protocol proved to be sufficiently feasible for use with the participant group, it will need to be adapted in the main study in order to obtain more reliable data. Recruitment, especially of participants for the control group, can be a major obstacle for future studies and requires careful planning. Researchweb.org, 270,501. Registered on 9 May 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Pain is a major symptom in adolescents with hypermobility spectrum disorder or hypermobile Ehlers-Danlos syndrome. Although the underlying mechanism causing generalized pain in children with hypermobility spectrum disorder or hypermobile Ehlers-Danlos syndrome is unclear, central sensitization has been suggested as a possible explanation. The aim of this study was to explore the feasibility of a study protocol for a future case-control study, investigating features of central sensitization in adolescents with hypermobility spectrum disorder or hypermobile Ehlers-Danlos syndrome.
METHODS
METHODS
Central sensitization features were measured in ten patients and nine healthy controls aged 13-17 years via experimental pain measurement quantifying primary and secondary hyperalgesia, endogenous pain modulation, and exercise-induced hyperalgesia. Descriptive statistics were used. Frequency, median, and range values were calculated.
RESULTS
RESULTS
Eleven out of 57 patients chose to participate. No control could be recruited through public schools. Therefore, a convenience sampling strategy was used for the recruitment of the control group. The process of assessing primary and secondary hyperalgesia, endogenous pain modulation, and exercise-induced hyperalgesia was well tolerated by all participants (patients and controls). When assessing endogenous pain modulation via conditioned pain modulation, two participants in the patient group and three in the control group did not achieve a pain experience ≥ 3 on the numerical rating scale when immersing their hands in cold water.
CONCLUSION
CONCLUSIONS
This study investigated the feasibility, safety, and toleration of experimental pain measurements in adolescents with hypermobility spectrum disorder or hypermobile Ehlers-Danlos syndrome. Although the test protocol proved to be sufficiently feasible for use with the participant group, it will need to be adapted in the main study in order to obtain more reliable data. Recruitment, especially of participants for the control group, can be a major obstacle for future studies and requires careful planning.
TRIAL REGISTRATION
BACKGROUND
Researchweb.org, 270,501. Registered on 9 May 2019.
Identifiants
pubmed: 37316864
doi: 10.1186/s40814-023-01320-3
pii: 10.1186/s40814-023-01320-3
pmc: PMC10265865
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97Subventions
Organisme : Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
ID : VGFOUREG-932162
Organisme : Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
ID : VGFOUREG-941028
Informations de copyright
© 2023. The Author(s).
Références
Pain. 2014 Jan;155(1):158-167
pubmed: 24076045
J Pain. 2014 Dec;15(12):1294-1304
pubmed: 25261342
Arch Phys Med Rehabil. 2004 Jul;85(7):1183-7
pubmed: 15241771
Clin Rheumatol. 2010 Apr;29(4):393-8
pubmed: 20077123
J Pain Symptom Manage. 1997 Aug;14(2):88-93
pubmed: 9262038
Pain. 2010 May;149(2):216-221
pubmed: 20188471
J Sports Sci Med. 2012 Dec 01;11(4):690-4
pubmed: 24150080
Pain. 2008 May;136(1-2):142-9
pubmed: 17720319
J Pediatr Gastroenterol Nutr. 2000 Sep;31(3):280-5
pubmed: 10997373
Arthritis Care Res (Hoboken). 2017 Mar;69(3):421-429
pubmed: 27483212
Int J Sports Med. 2018 Jun;39(6):473-481
pubmed: 29698982
Adv Neonatal Care. 2005 Dec;5(6):301-14
pubmed: 16338669
Prog Neurobiol. 2002 Apr;66(6):355-474
pubmed: 12034378
Pain. 2005 Jan;113(1-2):9-19
pubmed: 15621359
Man Ther. 2011 Oct;16(5):413-8
pubmed: 21632273
Pain Manag. 2014 Mar;4(2):97-111
pubmed: 24641434
Am J Med Genet C Semin Med Genet. 2017 Mar;175(1):48-69
pubmed: 28145611
Pain Med. 2015 May;16(5):923-33
pubmed: 25530341
Eur J Pain. 2009 Nov;13(10):1089-95
pubmed: 19726211
Clin J Pain. 2015 Mar;31(3):229-34
pubmed: 24699160
Brain Res Brain Res Rev. 2002 Oct;40(1-3):29-44
pubmed: 12589904
Clin Rheumatol. 2015 Jun;34(6):1121-9
pubmed: 24487572
Pain Rep. 2020 Sep 23;5(5):e823
pubmed: 33062901
Med Sci Sports Exerc. 1982;14(5):377-81
pubmed: 7154893
Eur J Pain. 2011 May;15(5):491-7
pubmed: 21035364
J Pain. 2005 Apr;6(4):218-27
pubmed: 15820909
Am J Med Genet A. 2019 Apr;179(4):561-569
pubmed: 30703284
J Child Health Care. 2020 Sep;24(3):444-457
pubmed: 31370685
Eur J Pain. 2019 Nov;23(10):1780-1789
pubmed: 31392790
Brain. 1984 Dec;107 ( Pt 4):1095-112
pubmed: 6509310
Eur J Pain. 2010 Apr;14(4):339
pubmed: 20227310
Int Rev Neurobiol. 2018;139:255-296
pubmed: 30146050
Pain. 2011 Mar;152(3 Suppl):S2-S15
pubmed: 20961685
J Oral Facial Pain Headache. 2019 Feb 6;33(2):143–152
pubmed: 30726861
J Pain. 2019 Nov;20(11):1249-1266
pubmed: 30904519
Am J Med Genet C Semin Med Genet. 2017 Mar;175(1):8-26
pubmed: 28306229
Eur J Pain. 2021 Jan;25(1):71-87
pubmed: 33034137
Am J Med Genet C Semin Med Genet. 2017 Mar;175(1):148-157
pubmed: 28145606
Clin J Pain. 2017 May;33(5):395-404
pubmed: 27518487
J Pediatr Psychol. 2009 Aug;34(7):749-59
pubmed: 18845586
J Pain. 2013 Sep;14(9):921-30
pubmed: 23685184